AIM: To systematically characterize specific pain patterns in the most frequent pancreatic diseases. METHODS: Pain in patients with chronic pancreatitis (n = 314), pancreatic cancer (n = 469), and other pancreatic tumors (n = 249) including mucinous (n = 20) and serous cystadenoma (n = 31), invasive (n = 37) and non-invasive intraductal papillary mucinous neoplasia (IPMN; n = 48), low stage (n = 18) and high stage neuroendocrine neoplasia (n = 44), and ampullary cancer (n = 51) was registered and correlated with clinicopathological data. Survival times were estimated by the Kaplan-Meier method. Patients alive at the follow-up time were censored. Survival curves were compared statistically using the log-rank test. RESULTS: Forty-nine point one percent of pancreatic cancer patients revealed no pain, whereas in chronic pancreatitis only 18.3% were pain free. In contrary, moderate/severe pain was registered in 15.1% in pancreatic cancer patients that was increased in chronic pancreatitis with up to 34.2%. Serous cystadenoma was asymptomatic in most cases (58.1%), whereas 78.9% of all mucinous cystadenoma patients suffered pain. In neuroendocrine neoplasia pain was not a key clinical symptom since 64% of low stage neuroendocrine neoplasia and 59% of high stage neuroendocrine neoplasia patients were pain free. Cancer localization in the pancreatic body and patients with malignant pancreatic neoplasms were associated with more severe pain. Tumor grading and stage did not show any impact on pain. Only in pancreatic cancer, pain was directly associated with impaired survival. CONCLUSION: Pancreatic pain depicts different patterns of abdominal pain sensation according to the respective pancreatic disorder and does not allow a unification of the term pancreatic pain.
AIM: To systematically characterize specific pain patterns in the most frequent pancreatic diseases. METHODS:Pain in patients with chronic pancreatitis (n = 314), pancreatic cancer (n = 469), and other pancreatic tumors (n = 249) including mucinous (n = 20) and serous cystadenoma (n = 31), invasive (n = 37) and non-invasive intraductal papillary mucinous neoplasia (IPMN; n = 48), low stage (n = 18) and high stage neuroendocrine neoplasia (n = 44), and ampullary cancer (n = 51) was registered and correlated with clinicopathological data. Survival times were estimated by the Kaplan-Meier method. Patients alive at the follow-up time were censored. Survival curves were compared statistically using the log-rank test. RESULTS: Forty-nine point one percent of pancreatic cancerpatients revealed no pain, whereas in chronic pancreatitis only 18.3% were pain free. In contrary, moderate/severe pain was registered in 15.1% in pancreatic cancerpatients that was increased in chronic pancreatitis with up to 34.2%. Serous cystadenoma was asymptomatic in most cases (58.1%), whereas 78.9% of all mucinous cystadenomapatients suffered pain. In neuroendocrine neoplasia pain was not a key clinical symptom since 64% of low stage neuroendocrine neoplasia and 59% of high stage neuroendocrine neoplasiapatients were pain free. Cancer localization in the pancreatic body and patients with malignant pancreatic neoplasms were associated with more severe pain. Tumor grading and stage did not show any impact on pain. Only in pancreatic cancer, pain was directly associated with impaired survival. CONCLUSION:Pancreatic pain depicts different patterns of abdominal pain sensation according to the respective pancreatic disorder and does not allow a unification of the term pancreatic pain.
Authors: Güralp O Ceyhan; Frank Bergmann; Mustafa Kadihasanoglu; Mert Erkan; Weon Park; Ulf Hinz; Thomas Giese; Michael W Müller; Markus W Büchler; Nathalia A Giese; Helmut Friess Journal: Gut Date: 2006-10-17 Impact factor: 23.059
Authors: Güralp O Ceyhan; Nathalia A Giese; Mert Erkan; Annika G Kerscher; Moritz N Wente; Thomas Giese; Markus W Büchler; Helmut Friess Journal: Ann Surg Date: 2006-08 Impact factor: 12.969
Authors: Furqan A Bhullar; Mahya Faghih; Venkata S Akshintala; Ahmed I Ahmed; Katie Lobner; Elham Afghani; Anna E Phillips; Phil A Hart; Mitchell L Ramsey; Benjamin L Bick; Louise Kuhlmann; Asbjørn M Drewes; Dhiraj Yadav; Søren S Olesen; Vikesh K Singh Journal: Pancreatology Date: 2021-11-18 Impact factor: 3.996
Authors: Andrew L Coveler; Jonathan Mizrahi; Bory Eastman; Smith Jim Apisarnthanarax; Shalini Dalal; Terry McNearney; Shubham Pant Journal: Oncologist Date: 2021-05-12
Authors: Maximilian Weniger; Leonard Reinelt; Jens Neumann; Lesca Holdt; Matthias Ilmer; Bernhard Renz; Werner Hartwig; Jens Werner; Alexandr V Bazhin; Jan G D'Haese Journal: Oxid Med Cell Longev Date: 2016-05-04 Impact factor: 6.543
Authors: Wasfi Alrawashdeh; Richard Jones; Laurent Dumartin; Tomasz P Radon; Pedro R Cutillas; Roger M Feakins; Branko Dmitrovic; Ihsan Ekin Demir; Guralp O Ceyhan; Tatjana Crnogorac-Jurcevic Journal: Mol Oncol Date: 2019-03-05 Impact factor: 6.603
Authors: Rebecca P Chow; Kevin Nguyen; Wenyu Gou; Erica Green; Katherine Morgan; William Lancaster; Kristi Helke; Charlie Strange; Hongjun Wang Journal: Biomedicines Date: 2021-11-16